

Adrian V S Hill

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7612716/adrian-v-s-hill-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

269
papers

27,820
citations

84
h-index

162
g-index

288
ext. papers

34,542
ext. citations

13.5
avg, IF

6.67
L-index

#	Paper	IF	Citations
269	Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.. <i>Frontiers in Immunology</i> , 2022 , 13, 795463	8.4	0
268	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.. <i>Molecular Therapy</i> , 2022 ,	11.7	1
267	Virus-like particle vaccines 2022 , 163-176		
266	CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination.. <i>JCI Insight</i> , 2022 ,	9.9	4
265	Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank.. <i>Nature Communications</i> , 2022 , 13, 1818	17.4	1
264	Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes.. <i>Frontiers in Genetics</i> , 2021 , 12, 719791	4.5	0
263	Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. <i>Scientific Reports</i> , 2021 , 11, 20877	4.9	0
262	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2021 , 396, 1979-1993	40	646
261	Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination. <i>EMBO Molecular Medicine</i> , 2021 , 13, e13390	12	2
260	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021 , 397, 881-891	40	495
259	Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021 , 9,	5.3	1
258	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1351-1362	40	316
257	Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. <i>Scientific Reports</i> , 2021 , 11, 10792	4.9	1
256	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1809-1818	40	65
255	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021 , 12, 4636	17.4	4
254	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021 , 397, 99-111	40	2110
253	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021 , 27, 279-288	50.5	135

252	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021 , 27, 270-278	50.5	225
251	Malaria is a cause of iron deficiency in African children. <i>Nature Medicine</i> , 2021 , 27, 653-658	50.5	8
250	Screening of viral-vectored <i>P. falciparum</i> pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites. <i>PLoS ONE</i> , 2021 , 16, e0254498	3.7	0
249	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021 , 8, e474-e485	7.8	62
248	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021 , 13, eabj7211	17.5	20
247	Poor CD4 T Cell Immunogenicity Limits Humoral Immunity to Transmission-Blocking Candidate Pf525 in Humans. <i>Frontiers in Immunology</i> , 2021 , 12, 732667	8.4	0
246	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021 , 27, 2032-2040	50.5	232
245	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy 2021 , 9,		2
244	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021 , 398, 981-990	40	68
243	Paths and timings of the peopling of Polynesia inferred from genomic networks. <i>Nature</i> , 2021 , 597, 522-526	50.4	9
242	The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans. <i>Scientific Reports</i> , 2020 , 10, 9004	4.9	2
241	Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency. <i>BMC Medicine</i> , 2020 , 18, 148	11.4	2
240	Generation of Novel NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 270	5.9	2
239	Estimating the burden of iron deficiency among African children. <i>BMC Medicine</i> , 2020 , 18, 31	11.4	21
238	Native American gene flow into Polynesia predating Easter Island settlement. <i>Nature</i> , 2020 , 583, 572-573	50.4	28
237	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial 2020 , 8,		14
236	Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of <i>Plasmodium falciparum</i> LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. <i>Infection and Immunity</i> , 2020 , 88,	3.7	5
235	Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. <i>Scientific Reports</i> , 2020 , 10, 5716	4.9	4

234	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 816-826	25.5	120
233	Vaccine innovations for emerging infectious diseases-a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2020 , 1462, 14-26	6.5	10
232	Identification of antigens presented by MHC for vaccines against tuberculosis. <i>Npj Vaccines</i> , 2020 , 5, 2	9.5	38
231	Targeting Antigen to the Surface of EVs Improves the Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020 , 16, 108-125	6.4	23
230	Immunological considerations for SARS-CoV-2 human challenge studies. <i>Nature Reviews Immunology</i> , 2020 , 20, 715-716	36.5	9
229	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020 , 396, 467-478	40	1274
228	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	15
227	Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. <i>Genes and Immunity</i> , 2020 , 21, 63-70	4.4	3
226	The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. <i>Science Advances</i> , 2019 , 5, eaaw0109	14.3	13
225	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1187-1197	7	39
224	A NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019 , 9, 96	5.9	7
223	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. <i>Vaccines</i> , 2019 , 7,	5.3	12
222	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. <i>Vaccines</i> , 2019 , 7,	5.3	16
221	TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 16479-16488	11.5	25
220	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. <i>Npj Vaccines</i> , 2019 , 4, 44	9.5	10
219	Iron Status and Associated Malaria Risk Among African Children. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1807-1814	11.6	19
218	Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and <i>Toxoplasma gondii</i> . <i>PLoS ONE</i> , 2019 , 14, e0210407	3.7	10
217	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. <i>Scientific Reports</i> , 2018 , 8, 3390	4.9	30

216	Language continuity despite population replacement in Remote Oceania. <i>Nature Ecology and Evolution</i> , 2018 , 2, 731-740	12.3	50
215	Genetic variation in is associated with bacteremia secondary to diverse pathogens in African children. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3601-E3603	11.5	30
214	Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4. <i>Nature Communications</i> , 2018 , 9, 1014	17.4	17
213	Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. <i>Vaccines</i> , 2018 , 6,	5.3	22
212	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018 , 201, 1315-1326	5.3	17
211	Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. <i>Infection and Immunity</i> , 2018 , 86,	3.7	18
210	Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. <i>Scientific Reports</i> , 2018 , 8, 3896	4.9	8
209	DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. <i>Diseases (Basel, Switzerland)</i> , 2018 , 6,	4.4	5
208	First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. <i>PLoS ONE</i> , 2018 , 13, e0208328	3.7	26
207	CXCR3 T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. <i>Frontiers in Immunology</i> , 2018 , 9, 1660	8.4	15
206	Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	43
205	Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8 T Cell Responses. <i>Scientific Reports</i> , 2018 , 8, 15020	4.9	14
204	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. <i>PLoS Neglected Tropical Diseases</i> , 2018 , 12, e0006870	4.8	22
203	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018 , 3, 49	9.5	25
202	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018 , 9, 2441	17.4	51
201	The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8 T Cells Present in the Liver. <i>Journal of Immunology</i> , 2017 , 198, 2006-2016	5.3	14
200	Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. <i>Vaccine Journal</i> , 2017 , 24,		13
199	Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. <i>Science Advances</i> , 2017 , 3, e1602096	14.3	35

198	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017 , 25, 547-559	11.7	26
197	Rational development of a protective <i>P. vivax</i> vaccine evaluated with transgenic rodent parasite challenge models. <i>Scientific Reports</i> , 2017 , 7, 46482	4.9	26
196	Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. <i>Nature Communications</i> , 2017 , 8, 14946	17.4	74
195	Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. <i>Scientific Reports</i> , 2017 , 7, 46621	4.9	94
194	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. <i>Vaccine</i> , 2017 , 35, 3780-3788	4.1	111
193	Cryopreservation-related loss of antigen-specific IFN γ -producing CD4 T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. <i>Vaccine</i> , 2017 , 35, 1898-1906	4.1	24
192	Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 328-339	10.2	95
191	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 3020-3032	4.4	47
190	Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M. <i>Vaccine</i> , 2017 , 35, 6208-6217	4.1	17
189	Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. <i>Scientific Reports</i> , 2017 , 7, 7284	4.9	9
188	An in vitro assay to measure antibody-mediated inhibition of <i>P. berghei</i> sporozoite invasion against <i>P. falciparum</i> antigens. <i>Scientific Reports</i> , 2017 , 7, 17011	4.9	7
187	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. <i>Frontiers in Immunology</i> , 2017 , 8, 1551	8.4	16
186	Human vaccination against <i>Plasmodium vivax</i> Duffy-binding protein induces strain-transcending antibodies. <i>JCI Insight</i> , 2017 , 2,	9.9	45
185	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. <i>Scientific Reports</i> , 2016 , 6, 20617	4.9	70
184	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. <i>Molecular Therapy</i> , 2016 , 24, 1470-7	11.7	40
183	Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016 , 41, 47-54	7.8	103
182	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. <i>Journal of Infectious Diseases</i> , 2016 , 214, 772-81	7	63
181	Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. <i>American Journal of Human Genetics</i> , 2016 , 98, 1092-1100	11	30

180	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016 , 374, 1635-46	59.2	232
179	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. <i>Vaccine</i> , 2016 , 34, 49-55	4.1	12
178	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 31-42	25.5	152
177	Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. <i>Lancet Respiratory Medicine, the</i> , 2016 , 4, 259-71	35.1	305
176	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016 , 4,	5.3	27
175	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. <i>PLoS ONE</i> , 2016 , 11, e0167951	3.7	34
174	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. <i>Hepatology</i> , 2016 , 63, 1455-70	11.2	32
173	Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. <i>Vaccine</i> , 2016 , 34, 2296-8	4.1	21
172	Genomic modulators of gene expression in human neutrophils. <i>Nature Communications</i> , 2015 , 6, 7545	17.4	92
171	Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. <i>Scientific Reports</i> , 2015 , 5, 11820	4.9	40
170	Genetic susceptibility to invasive Salmonella disease. <i>Nature Reviews Immunology</i> , 2015 , 15, 452-63	36.5	58
169	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. <i>Malaria Journal</i> , 2015 , 14, 33	3.6	27
168	Searching for the human genetic factors standing in the way of universally effective vaccines. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015 , 370,	5.8	29
167	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015 , 47, 717-726	36.3	244
166	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. <i>Science Translational Medicine</i> , 2015 , 7, 286re5	17.5	94
165	Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. <i>Vaccine</i> , 2015 , 33, 3248-55	4.1	24
164	Workshop report: Malaria vaccine development in Europe--preparing for the future. <i>Vaccine</i> , 2015 , 33, 6137-44	4.1	5
163	Profiling the host response to malaria vaccination and malaria challenge. <i>Vaccine</i> , 2015 , 33, 5316-20	4.1	15

162	Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity". <i>Vaccine</i> , 2015 , 33, 7444-51	4.1	39
161	Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. <i>Scientific Reports</i> , 2015 , 5, 16756	4.9	20
160	Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. <i>Frontiers in Microbiology</i> , 2015 , 6, 965	5.7	13
159	Rare variants in MYD88, IRAK4 and IKBKG and susceptibility to invasive pneumococcal disease: a population-based case-control study. <i>PLoS ONE</i> , 2015 , 10, e0123532	3.7	3
158	Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PflUIS3, PFLSA1 and PFLSAP2 in Multiple Strains of Mice. <i>PLoS ONE</i> , 2015 , 10, e0144515	3.7	4
157	Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1076-86	7	100
156	Variants in the Mannose-binding Lectin Gene MBL2 do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. <i>Clinical Infectious Diseases</i> , 2015 , 61, 695-703	11.6	13
155	Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 93, 1254-1259	3.2	5
154	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 53-60	35.1	108
153	The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. <i>Vaccine</i> , 2015 , 33, 1121-8	4.1	19
152	Development of an in vitro assay and demonstration of Plasmodium berghei liver-stage inhibition by TRAP-specific CD8+ T cells. <i>PLoS ONE</i> , 2015 , 10, e0119880	3.7	16
151	Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. <i>Molecular Therapy</i> , 2014 , 22, 2142-2154	11.7	51
150	Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. <i>Molecular Therapy</i> , 2014 , 22, 1992-2003	11.7	39
149	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. <i>Scientific Reports</i> , 2014 , 4, 6154	4.9	34
148	Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain. <i>PLoS ONE</i> , 2014 , 9, e100538	3.7	31
147	4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques. <i>PLoS ONE</i> , 2014 , 9, e105520	3.7	5
146	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. <i>Science Translational Medicine</i> , 2014 , 6, 261ra153	17.5	233
145	Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. <i>Molecular Therapy</i> , 2014 , 22, 668-674	11.7	130

144	Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. <i>Molecular Therapy</i> , 2014 , 22, 464-475	11.7	157
143	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to <i>Plasmodium falciparum</i> using sporozoites administered by intramuscular injection. <i>Frontiers in Microbiology</i> , 2014 , 5, 686	5.7	78
142	Efficacy of a <i>Plasmodium vivax</i> malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic <i>Plasmodium berghei</i> parasites. <i>Infection and Immunity</i> , 2014 , 82, 1277-86	3.7	44
141	RNA and imidazoquinolines are sensed by distinct TLR7/8 ectodomain sites resulting in functionally disparate signaling events. <i>Journal of Immunology</i> , 2014 , 192, 5963-73	5.3	31
140	Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. <i>Immunology</i> , 2014 , 141, 628-44	7.8	33
139	Towards a multi-antigen multi-stage malaria vaccine. <i>Malaria Journal</i> , 2014 , 13,	3.6	6
138	Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors. <i>Vaccine Journal</i> , 2014 , 21, 901-3		12
137	Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. <i>Molecular Therapy</i> , 2014 , 22, 233-8	11.7	80
136	External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance. <i>PLoS ONE</i> , 2014 , 9, e97398	3.7	25
135	Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. <i>PLoS ONE</i> , 2014 , 9, e107903	3.7	46
134	A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. <i>PLoS ONE</i> , 2014 , 9, e115161	3.7	42
133	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013 , 4, 2836	17.4	223
132	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. <i>Virology Journal</i> , 2013 , 10, 349	6.1	37
131	Identifying recent adaptations in large-scale genomic data. <i>Cell</i> , 2013 , 152, 703-13	56.2	259
130	Identification of targets of CD8+ T cell responses to malaria liver stages by genome-wide epitope profiling. <i>PLoS Pathogens</i> , 2013 , 9, e1003303	7.6	54
129	Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. <i>Journal of Infectious Diseases</i> , 2013 , 208, 340-5	7	38
128	Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection. <i>Journal of Immunology</i> , 2013 , 190, 1135-47	5.3	18
127	The utility of <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment. <i>Scientific Reports</i> , 2013 , 3, 1706	4.9	20

126	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013 , 8, e65960	3.7	68
125	Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. <i>PLoS ONE</i> , 2013 , 8, e67888	3.7	60
124	Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. <i>PLoS ONE</i> , 2013 , 8, e57726	3.7	60
123	Coated microneedle arrays for transcutaneous delivery of live virus vaccines. <i>Journal of Controlled Release</i> , 2012 , 159, 34-42	11.7	124
122	Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. <i>Biotechnology and Bioengineering</i> , 2012 , 109, 719-28	4.9	31
121	ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. <i>Molecular Therapy</i> , 2012 , 20, 2355-68	11.7	155
120	Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies. <i>Travel Medicine and Infectious Disease</i> , 2012 , 10, 192-6	8.4	10
119	Evolution, revolution and heresy in the genetics of infectious disease susceptibility. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012 , 367, 840-9	5.8	98
118	Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , 2012 , 8, 706-14	4.4	56
117	Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. <i>Molecular Therapy</i> , 2012 , 20, 1633-47	11.7	35
116	Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. <i>PLoS ONE</i> , 2012 , 7, e33555	3.7	37
115	Identification of 34 novel proinflammatory proteins in a genome-wide macrophage functional screen. <i>PLoS ONE</i> , 2012 , 7, e42388	3.7	7
114	T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein. <i>PLoS ONE</i> , 2012 , 7, e44943	3.7	21
113	A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. <i>PLoS ONE</i> , 2012 , 7, e48322	3.7	92
112	Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. <i>Science Translational Medicine</i> , 2012 , 4, 115ra1	17.5	310
111	Human genetic susceptibility to infectious disease. <i>Nature Reviews Genetics</i> , 2012 , 13, 175-88	30.1	327
110	Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. <i>Journal of Infectious Diseases</i> , 2012 , 205, 772-81	7	175
109	Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection. <i>Journal of Immunology</i> , 2012 , 188, 5041-53	5.3	18

108	Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. <i>Science Translational Medicine</i> , 2012 , 4, 115ra2	17.5	210
107	Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. <i>Clinical Infectious Diseases</i> , 2012 , 55, 19-25	11.6	191
106	Bayesian refinement of association signals for 14 loci in 3 common diseases. <i>Nature Genetics</i> , 2012 , 44, 1294-301	36.3	347
105	Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. <i>PLoS ONE</i> , 2012 , 7, e31208	3.7	126
104	Comparison of clinical and parasitological data from controlled human malaria infection trials. <i>PLoS ONE</i> , 2012 , 7, e38434	3.7	60
103	A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. <i>PLoS ONE</i> , 2012 , 7, e40385	3.7	209
102	Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. <i>PLoS ONE</i> , 2012 , 7, e50447	3.7	17
101	The blood-stage malaria antigen PFRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. <i>Nature Communications</i> , 2011 , 2, 601	17.4	188
100	A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. <i>Vaccine</i> , 2011 , 29, 7514-22	4.1	37
99	Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. <i>PLoS ONE</i> , 2011 , 6, e20977	3.7	39
98	Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. <i>PLoS ONE</i> , 2011 , 6, e22442	3.7	60
97	Viral vectors as vaccine platforms: deployment in sight. <i>Current Opinion in Immunology</i> , 2011 , 23, 377-82	7.8	157
96	Vaccines and global health. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011 , 366, 2733-42	5.8	20
95	CD8+ T effector memory cells protect against liver-stage malaria. <i>Journal of Immunology</i> , 2011 , 187, 1347-57	5.7	104
94	Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. <i>Journal of Immunology</i> , 2011 , 187, 3738-50	5.3	33
93	Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. <i>Molecular Therapy</i> , 2011 , 19, 2269-76	11.7	134
92	Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1-7	11.6	364
91	Vaccines against malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011 , 366, 2806-14	5.8	144

90	The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. <i>Journal of Immunology</i> , 2011 , 187, 2602-16	5.3	48
89	Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. <i>PLoS ONE</i> , 2011 , 6, e22271	3.7	73
88	Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. <i>Nature Genetics</i> , 2010 , 42, 739-741	36.3	276
87	Prime-boost vectored malaria vaccines: progress and prospects. <i>Hum Vaccin</i> , 2010 , 6, 78-83		171
86	An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. <i>Human Molecular Genetics</i> , 2010 , 19, 720-30	5.6	20
85	Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. <i>Infection and Immunity</i> , 2010 , 78, 145-53	3.7	151
84	Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. <i>Vaccine</i> , 2010 , 29, 256-65	4.1	58
83	Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. <i>Journal of Immunology</i> , 2010 , 185, 7583-95	5.3	73
82	Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. <i>Science Translational Medicine</i> , 2010 , 2, 19ra12	17.5	118
81	Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 724-33	10.2	97
80	Consanguinity and susceptibility to infectious diseases in humans. <i>Biology Letters</i> , 2009 , 5, 574-6	3.6	52
79	Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. <i>Cell Host and Microbe</i> , 2009 , 5, 95-105	23.4	57
78	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. <i>Vaccine</i> , 2009 , 27, 5589-98	4.1	14
77	Jenner reborn: a new vaccine institute. <i>Lancet, The</i> , 2009 , 373, 445-6	4.0	
76	Effective induction of high-titer antibodies by viral vector vaccines. <i>Nature Medicine</i> , 2008 , 14, 819-21	50.5	128
75	Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. <i>European Journal of Immunology</i> , 2008 , 38, 732-41	6.1	86
74	Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. <i>PLoS ONE</i> , 2008 , 3, e1493	3.7	83
73	Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). <i>PLoS ONE</i> , 2008 , 3, e1638	3.7	76

72	Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. <i>PLoS ONE</i> , 2008 , 3, e2921	3.7	42
71	The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by <i>Plasmodium falciparum</i> . <i>Journal of Immunology</i> , 2007 , 179, 4193-201	5.3	77
70	Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. <i>Infection and Immunity</i> , 2007 , 75, 5819-26	3.7	39
69	Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. <i>PLoS ONE</i> , 2007 , 2, e707	3.7	53
68	A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. <i>PLOS Clinical Trials</i> , 2006 , 1, e29		110
67	Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length <i>Plasmodium falciparum</i> circumsporozoite protein. <i>Infection and Immunity</i> , 2006 , 74, 2706-16	3.7	54
66	Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage <i>Plasmodium falciparum</i> correlate with parasitological and clinical outcomes. <i>Journal of Immunology</i> , 2006 , 177, 5736-45	5.3	117
65	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. <i>Vaccine</i> , 2006 , 24, 2850-9	4.1	72
64	PTPN22 and invasive bacterial disease. <i>Nature Genetics</i> , 2006 , 38, 499-500	36.3	48
63	Pre-erythrocytic malaria vaccines: towards greater efficacy. <i>Nature Reviews Immunology</i> , 2006 , 6, 21-32	36.5	107
62	Aspects of genetic susceptibility to human infectious diseases. <i>Annual Review of Genetics</i> , 2006 , 40, 469-84	36.5	201
61	Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. <i>Vaccine</i> , 2005 , 23, 857-64	4.1	56
60	Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. <i>Journal of Immunology</i> , 2005 , 175, 599-606	5.3	59
59	Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. <i>Immunology and Cell Biology</i> , 2005 , 83, 307-12	5	43
58	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. <i>Hepatology</i> , 2005 , 41, 1383-90	11.2	103
57	Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. <i>Journal of Infectious Diseases</i> , 2005 , 191, 619-26	7	135
56	Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. <i>Journal of Immunology</i> , 2005 , 174, 449-55	5.3	133
55	Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. <i>Journal of Immunology</i> , 2005 , 175, 7264-73	5.3	86

54	Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. <i>Journal of Immunology</i> , 2005 , 175, 5675-80	5.3	111
53	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 4836-41	11.5	212
52	QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 191-198	3.2	84
51	Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 191-8	3.2	65
50	A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 290-5	11.5	53
49	Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. <i>Nature Medicine</i> , 2004 , 10, 1240-4	50.5	475
48	Quantitative Association Tests of Immune Responses to Antigens of Mycobacterium Tuberculosis: A Study of Twins in West Africa. <i>Twin Research and Human Genetics</i> , 2004 , 7, 578-588		3
47	Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against M. Tuberculosis. <i>Clinical Science</i> , 2003 , 104, 51P-51P		
46	Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. <i>Clinical Science</i> , 2003 , 104, 56P-56P		
45	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. <i>Nature Medicine</i> , 2003 , 9, 729-35	50.5	495
44	EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003 , 68, 421-430	3.2	30
43	Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003 , 68, 421-30	3.2	23
42	Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. <i>Vaccine</i> , 2002 , 20, 1039-45	4.1	138
41	Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. <i>Immunology and Cell Biology</i> , 2001 , 79, 569-75	5	18
40	Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. <i>Journal of Medical Virology</i> , 2001 , 65, 664-70	19.7	23
39	A major susceptibility locus for leprosy in India maps to chromosome 10p13. <i>Nature Genetics</i> , 2001 , 27, 439-41	36.3	146
38	Genetics of susceptibility to human infectious disease. <i>Nature Reviews Genetics</i> , 2001 , 2, 967-77	30.1	380
37	The genomics and genetics of human infectious disease susceptibility. <i>Annual Review of Genomics and Human Genetics</i> , 2001 , 2, 373-400	9.7	184

36	Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. <i>Lancet, The</i> , 2001 , 358, 1927-34	40	413
35	Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. <i>Infection and Immunity</i> , 2001 , 69, 681-6	3.7	198
34	High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. <i>European Journal of Immunology</i> , 2000 , 30, 2713-21	6.1	87
33	Improved method for distinguishing the human source of mosquito blood meals between close family members. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2000 , 94, 572-4	2	20
32	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. <i>Nature Medicine</i> , 2000 , 6, 337-42	50.5	461
31	Vaccines against intracellular infections requiring cellular immunity. <i>Nature</i> , 2000 , 406, 793-8	50.4	296
30	Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. <i>Journal of Infectious Diseases</i> , 1999 , 179, 287-90	7	207
29	Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. <i>Immunological Reviews</i> , 1999 , 170, 29-38	11.3	171
28	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. <i>Nature Medicine</i> , 1999 , 5, 565-71	50.5	79
27	Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. <i>Journal of Infectious Diseases</i> , 1999 , 180, 1656-64	7	133
26	The immunogenetics of resistance to malaria. <i>Proceedings of the Association of American Physicians</i> , 1999 , 111, 272-7		45
25	T-cell receptor variable alpha (TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations. <i>Immunogenetics</i> , 1998 , 47, 124-30	3.2	5
24	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. <i>Nature Medicine</i> , 1998 , 4, 397-402	50.5	584
23	Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. <i>European Journal of Immunology</i> , 1998 , 28, 4345-55	6.1	72
22	Glucose-6-phosphate dehydrogenase deficiency and malaria. <i>Journal of Molecular Medicine</i> , 1998 , 76, 581-8	5.5	157
21	The immunogenetics of human infectious diseases. <i>Annual Review of Immunology</i> , 1998 , 16, 593-617	34.7	439
20	Heterogeneity of microsatellite mutations within and between loci, and implications for human demographic histories. <i>Genetics</i> , 1998 , 148, 1269-84	4	107
19	Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use 1998 , 28, 4345		6

18	Genetic analysis of host-parasite coevolution in human malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1997 , 352, 1317-25	5.8	47
17	A protein particle vaccine containing multiple malaria epitopes. <i>Nature Biotechnology</i> , 1997 , 15, 1280-4	44.5	134
16	Heterozygote advantage for HLA class-II type in hepatitis B virus infection. <i>Nature Genetics</i> , 1997 , 17, 11-2	36.3	254
15	A distinctive peptide binding motif for HLA-DRB1*0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. <i>Immunogenetics</i> , 1997 , 45, 229-32	3.2	13
14	Genetic susceptibility to multifactorial diseases. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997 , 91, 369-71	2	1
13	Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. <i>BMJ: British Medical Journal</i> , 1997 , 315, 96-7		48
12	Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. <i>European Journal of Immunology</i> , 1996 , 26, 773-9	6.1	44
11	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. <i>European Journal of Immunology</i> , 1996 , 26, 1951-9	6.1	83
10	HIV and HLA: confusion or complexity?. <i>Nature Medicine</i> , 1996 , 2, 395-6	50.5	30
9	Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. <i>Nature Medicine</i> , 1995 , 1, 374-5	50.5	47
8	Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. <i>European Journal of Immunology</i> , 1995 , 25, 1783-7	6.1	38
7	Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. <i>Nature</i> , 1994 , 371, 508-10	50.4	1041
6	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. <i>Nature</i> , 1992 , 360, 434-9	50.4	561
5	Common west African HLA antigens are associated with protection from severe malaria. <i>Nature</i> , 1991 , 352, 595-600	50.4	1273
4	Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leukocyte antigen locus		1
3	Human genetic susceptibility to infectious disease		1
2	Identification of host-pathogen-disease relationships using a scalable Multiplex Serology platform in UK Biobank		11
1	Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkina Faso volunteers		7

